The quality of the antitumor immune response is decisive when developing new immunotherapies for cancer. Oncolytic adenoviruses cause a potent immunogenic stimulus and arming them with costimulatory molecules reshapes the immune response further. We evaluated peripheral blood T-cell subsets of 50 patients with refractory solid tumors undergoing treatment with oncolytic adenovirus. These data were compared to changes in antiviral and antitumor T cells, treatment efficacy, overall survival, and T-cell subsets in pre-and post-treatment tumor biopsies. Treatment caused a significant (P < 0.0001) shift in T-cell subsets in blood, characterized by a proportional increase of CD8 + cells, and decrease of CD4 + cells. Concomitant treatment with cyclophosphamide and temozolomide resulted in less CD4 + decrease (P = 0.041) than cyclophosphamide only. Interestingly, we saw a correlation between T-cell changes in peripheral blood and the tumor site. This correlation was positive for CD8 + and inverse for CD4 + cells. These findings give insight to the interconnections between peripheral blood and tumor-infiltrating lymphocyte (TIL) populations regarding oncolytic virotherapy. In particular, our data suggest that induction of T-cell response is not sufficient for clinical response in the context of immunosuppressive tumors, and that peripheral blood T cells have a complicated and potentially misleading relationship with TILs.
INTRODUCTION
The overall antitumor immune response results from activity of both the innate and adaptive immune systems. 1 The latter has been studied rigorously and a conceptual framework of cancer immunosurveillance has been developed. 2 Along with the cancer preventing normal immune functions ("immunosuppression"), the immune system can also promote tumor growth. 3 One of the main immune cell population affecting the balance between immunosuppression and antitumor immunity is CD3 + T-lymphocytes. 4 The key elements of an effective antitumor T-cell response are currently not thoroughly deciphered, especially in the context of humans. However, cytotoxic CD8-type and helper CD4-type responses have been viewed as crucial players. [4] [5] [6] With regards to immunosuppression, the most important T-cell type is likely the regulatory T cell. [7] [8] [9] One interesting concept concerning T-cell responses is T-cell trafficking from, for example, peripheral blood to tumor sites. Tumor-infiltrating lymphocytes (TILs) have been established as a valuable marker of prognosis 10, 11 and it has even been proposed that TILs should be implemented as a routine method for evaluating treatment efficacy and response, 12 or grown out for use as a therapeutic. 13 Adenoviruses provide a potent immunogenic stimulus which can enhance antitumoral immune responses. 14 Further, immunological factors have been shown to be critical for the efficacy of oncolytic adenoviruses themselves, 15 which provide immunostimulatory signals to the innate and adaptive immune system. 16, 17 Arming oncolytic adenoviruses with costimulatory molecules, such as granulocyte macrophage colony-stimulating factor (GM-CSF) or CD40 ligand, results in further activation of different immune mechanisms. [17] [18] [19] [20] Oncolytic adenoviruses have been shown to induce a Th1-type response and cause accumulation of cytotoxic T cells at tumor sites in both mice and humans. 17, 21 To enhance the immunologic effects of adenoviruses, concomitant treatments with low-dose chemotherapeutics have also been utilized. 22, 23 However, not much is known about the effects of oncolytic adenoviruses on the immunostimulatory and immunosuppressive T-cell subsets in human cancer patients.
We examined peripheral blood T cell levels in 50 human patients after their first treatment with an oncolytic adenovirus. T-cell number and activity were measured by both flow cytometry and enzyme-linked immunospot assay (ELISPOT) from pre-and post-treatment blood samples. Further, we investigated the correlation between T-cell levels and clinical response determined by computer tomography (CT) or positron emission tomography (PET) response criteria. We also had access to pre-and 
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RESULTS
Treatment with oncolytic adenovirus causes changes in blood T-cell subpopulations
Previous work has suggested that therapy with oncolytic adenovirus can cause changes in blood cytotoxic CD8 + T cells but the affected subpopulations have not been studied. 20, 23 Pre-and posttreatment T-cell subpopulations were quantified from samples after first treatments with Ad5/3-d24-GMCSF (CGTG-102), 24 Ad5/3-hTERT-CD40L (CGTG-401), 25 or Ad5/3-E2F-d24-GMCSF (CGTG-602) 19 in a total of 50 patients ( Table 1) . CD4 + and CD8 + populations were significantly altered (P < 0.0001) between pre-and post-treatment samples in all patients (Figure 1a) , whereas Treg and Th1 populations showed no clear differences. When analyzed individually, different viruses presented similar patterns of T-cell changes (Figure 1b-d) . Also, the changes in populations were comparable, when measured with absolute cell counts (Supplementary Figure S1a-d) .
The proportion of CD4 + cells decreased in 39/50 patients, whereas the proportion of CD8 + cells increased in 38/50 patients. When the changes are presented as differences in percentages of parent population, the changes in CD4 + and CD8 + populations are inversely correlated (Supplementary Figure S2) . This effect is influenced by the way the data is presented, since the two cell populations represent >90% of CD3 + cells in most patients and thus the proportion of one cell type influences that of the other. When one population increases, the relative proportion of the other decreases, regardless of absolute numbers. When presented as absolute flow cytometry cell count changes, the correlation is absent, but the distribution of changes is, however, similar (Supplementary Figure S3) . Changes in Treg and Th1 populations showed no correlation with each other (Supplementary Figure S4) .
Generally, the relative amounts of CD4 + IL17 + Th17 cells were low (0.1-0.2%) and virus treatment did not cause much increase of these cells in blood (Supplementary Figure S5) . Interestingly, one patient showed a markedly elevated Th17 level before treatment (1.1%) coupled with post-treatment decrease (to 0.5%). This patient was a 10-year-old female diagnosed with osteosarcoma. She was treated with CGTG-102 and had a minor imaging response and overall survival of 277 days. Unfortunately, we did not have access to a tumor biopsy to see if the reason for reduction in blood Th17 cells was trafficking to the tumor.
Virus type and concomitant treatments affect T-cell changes
Changes in CD4 + and CD8 + subpopulations seemed to differ according to the used virus type (Figure 2a) . Patients treated with CGTG-102 or CGTG-401 had deeper median decreases in CD4 + cells together with higher median increases in CD8 + cells, than patients treated with CGTG-602, which has dual modifications for tumor selectivity compared to the other two viruses. Treatment doses for different viruses had some variation, but we saw no correlation between the treatment dose and changes in T-cell subpopulations. Difference in CD8 + change was borderline significant (P = 0.0745) between CGTG-102 and CGTG-602 groups. When grouped by the inserted cytokine, GM-CSF or CD40L, the treatment groups displayed no clear differences in T-cell changes (data not shown).
The impact of concomitant immunomodulatory virus sensitizers on T-cell subpopulations was assessed. Patients who received no concomitant treatments had the largest changes in T cells, compared to patients receiving concomitant cyclophosphamide (metronomic per oral, low-dose intravenous bolus or both) or concomitant cyclophosphamide together with low dose pulse temozolomide 22, 23 (Figure 2b) . When comparing the cyclophosphamide + temozolomide group with the cyclophosphamide Ad5/3-E2F-d24-GMCSF (CGTG-602) 22 only group, we saw a significant difference in CD4 + decrease (P = 0.041) and a clear but non-significant difference in CD8 + increase.
Increases in blood CD4 + T cells are seen only after 6 weeks
We observed an uneven distribution of CD4 + T cells when plotted against time of post-treatment blood sample acquisition (Supplementary Figure S6) . Patients whose post-treatment samples were obtained before 43 days (38% of all patients) had no increases in blood CD4 + cells. With samples taken beyond 43 days, 35% of patients had an increase in CD4 + cells, suggesting that increase in CD4 + cells (including, e.g., Helper T-cells and T-Regs) takes time. Since the proportional CD8 + changes were inversely associated with CD4 + changes, we saw a similar but inversed pattern in CD8 + changes: increases in CD8 + were seen at all time points but decreases in the proportion of CD8 + cells (caused for example by increases in the proportion of CD4 + ) were seen only after 43 days (Supplementary Figure S7) .
Antivirus and antitumor T-cell reactivity is associated with smaller changes in CD8 + and CD4 + proportions
We measured antiviral and antitumoral T-cell responses in peripheral blood by interferon-γ ELISPOT from pre-and post-treatment samples and patients were divided into no change, increase, and decrease groups. In anti-Ad5 penton ELISPOT, 11 patients had no change while 20 and 18 patients showed increase and decrease, respectively (Figure 2c) . Interestingly, the largest changes in blood T-cell subpopulations were associated with no change in ELISPOT, whereas changes were smallest in the "decrease in anti-Ad5 ELISPOT" group. However, differences between the groups were not statistically significant. To estimate antitumoral T-cell responses, we used ELISPOT for Survivin, a proposed pan-carcinoma antigen. 17, 20, 22, 23, 26 Seventeen patients had no change while 10 and 22 patients had increase and decrease, respectively (Figure 2d) . The smallest changes in T-cell subpopulations were associated with the "increase in anti-Survivin activity" group. Although the differences between groups were not statistically significant the trend was again the same: patients with emphatic changes in proportional T-cell subsets in blood were less likely to show signs of induction of adaptive antitumor immunity when measured functionally with ELISPOT.
Comparison of blood and tumor biopsy T-cell subpopulations suggests an inverse correlation for CD4 + blood/tumor levels and a direct correlation for CD8 + blood/tumor levels Pre-and post-treatment tumor biopsies were available from five patients. Data from immunohistochemical staining of biopsy samples, flow cytometry, and information on treatment regimes as well as clinical responses is presented in Table 2 . To compare relative changes in biopsy staining changes, the changes were converted to percentual difference between pre-and posttreatment scores. Relative changes in both biopsy stainings and flow cytometry results had a trend for inverse correlation for the CD4 + T cells (Figure 3a) . In contrast, for the CD8 + cells, the relative changes in peripheral blood flow cytometry results and biopsy staining scores show a trend for positive correlation ( Figure 3b) . P values for correlation were borderline significant despite the small sample size (0.084 and 0.083 for CD4 + and CD8 + populations, respectively) and it would be interesting to study these associations in more patients, although obtaining extensive tumor biopsies is a known problem in clinical oncology. However, it is interesting that even in this small series, there seemed to be correlation between an increase in CD4 + cells at tumor biopsy hotspots and treatment benefits, as estimated by PET scanning. In all three patients with disease control or metabolic response, there was an increase in CD4 + cells at the tumor, while in the two patients where there was progressive metabolic disease, there was a decrease ( Table 2) .
Interestingly, there seemed to be possible correlation also between macrophage markers CD68 and CD163 and treatments benefits, as both markers increased in patientts with stable disease or better in PET, but they did not increase in patients with progression in imaging. Moreover, patient O340, who had the best imaging response and longest overall survival, had the largest percentual increase in biopsy staining scores of monocyte/ macrophage lineage markers CD68 and CD163 (Figure 4) . The B-cell marker CD19 or the lymphocyte activation marker CD25 displayed no clear correlation with treatment benefit.
T-cell subpopulation changes in blood lack correlation with treatment responses or survival
Radiological response evaluation data fulfilling modified RECIST1.1 or PET criteria were available for 37 patients (Supplementary Table S1 ). Median changes of all T-cell subpopulations in blood were close to the overall median in patients featuring disease control or progression, and accordingly the groups were not significantly different from each other. Both groups presented a clear decrease in CD4 + T cells and increase CD8 + T cells as above. When grouped by CD4 + or CD8 + change status (decrease or increase, Supplementary Figure S2) , we saw no difference in overall survival (Supplementary Figure S8) .
DISCUSSION
The presence of TILs has been generally regarded as a marker of good prognosis in the context of most cancer types. 12 However, the composition of different types of cells in the infiltrating lymphocyte compartment is probably just as important as the overall number, if not more so, explaining why some investigators have also reported association of TIL numbers and poor prognosis. 5, 6 The immunological environment could also have an effect on the efficacy of chemotherapy. 27, 28 Different chemotherapeutics as well as oncolytic viruses affect the differentiation, 29 activation 18, 20 , and migration 30 of lymphocytes to tumors. Clearly, for tumor therapy, lymphocytes present at tumors are more relevant than cells passing through blood, as the former represents the target organ and the latter a mere conduit. However, blood is readily available from trial patients, while tumor biopsies are notoriously difficult to obtain, especially from solid tumors not related to the skin. Therefore, as a first step toward optimization of immunotherapies, it would be useful to understand the correlation between blood and tumor lymphocytes.
Here we have shown that treatment with oncolytic adenovirus causes a change in peripheral blood T-cell compartments. This transition involves a relative decrease in CD4 + cells, including helper T cells, and a relative increase in CD8 + cells, including antiviral and antitumor cytotoxic T cells. Our results are in line with previous data on oncolytic adenoviruses and their effects on blood lymphocytes. 20, 23 The increase in CD8 + cells in blood could be explained simplistically by the highly immunogenic nature of adenovirus, resulting in an increase in both antiviral and antitumor cells. Previous reports have indicated how antiviral immunity contributes to antitumor immunity through epitope spreading and danger signaling through pathogen associated molecular pattern recognition receptors. 18, 20, 31 Based on the low levels of Th17 cells in pre-and post-treatment samples, it is possible that these cells are not a central part of the immunomodulatory effects of adenovirus therapy.
Reduction of CD4 + cells in blood, including, e.g., Helper T cells, but not T-Regs (Figure 2) , is more complicated. One component of the overall situation could be that tumor infection causes CD4 + cells to migrate from the blood to the tumor site, as discussed below. The different behavior of CD8 + cells and CD4 + cells is compatible with the former being more easily mobilized on a systemic level, resulting in a general increase in number and activity in both target tissues but also the "highways", i.e., blood. In other words, general mobilization results also in increased traffic on the highways. In contrast, the capacity of CD4 + cells to increase in number could be more limited, resulting in redistribution dominating over general mobilization. This theory is compatible with the notion that Helper T cells are the controllers of the direct cytotoxic activity of CD8 + cells. Due to limited amount of available patient samples, we did not evaluate Th2 type T cells in patients. The characteristics of Th2 type response in adenovirus therapy and, especially, the effects on Th1/Th2 balance should be investigated in future experiments.
Our results suggest that virus design affects changes in T-cell subsets. The less selective CGTG-102, which lacks a tumor specific promoter in front of the viral E1A seemed to cause more prominent increases in CD8 + cells, than the more selective CGTG-602, which features dual replication control: an E2F tumor specific promoter and an E1A constant region 2 deletion. 19 The main consequence of these differences is that with CGTG-102, E1A is expressed even in nonpermissive cells, and since E1A is trigger for expression of several other adenovirus proteins and can cause immunological effects on its own, this design results in some "leaky" expression of immunogenic adenovirus proteins. 32 In addition to the oncolytic effects of the virus construct, the inserted cytokines can influence the effects of the treatment. However, we found no clear differences in blood or biopsy T-cell levels between patients treated with viruses coding for GM-CSF or CD40L. One explanation for the lack of difference would be that despite the different spectrum of immunological impacts of the two cytokines, the pathways converge into similar effector level consequences. It can be further hypothesized that responses to the expressed cytokines depend largely on the pretreatment immunological status in the tumor level. High local production of the inserted transgenes, in contrast to the therapy with recombinant cytokines, is also crucial for beneficial immunological outcomes.
Further improvements in virus design could relate to additional enhancement of replication selectivity and exploitation of pathways of the innate immunity that are not readily activated in the tumors. There is also a need for more in-depth understanding of the specific immunomodulatory action of the different transgenes when delivered from the immunogenic oncolytic platform. Therapies with oncolytic viruses could also be advanced by combining with other therapies such as treatment with monoclonal antibodies or immune cell-based therapies.
Low-dose cyclophosphamide and temozolomide 22, 23 given to enhance the efficacy of viral treatment had their own consequences for immune cell compartments. Especially, their combination resulted in less prominent changes in blood CD4 + cells. Previous in vivo and ex vivo experiments with murine and human cells have provided contradictory conclusions on the effects of temozolomide on cells of the immune system. [33] [34] [35] [36] Some of the discrepancies are probably explained by dose since "active dose" or "cytotoxic" chemotherapy is typically given at maximal tolerated dose, while immunomodulatory chemotherapy uses much lower doses and different schedules. Thus, the most relevant reference in this context involves use of low-dose pulse temozolomide, used as an autophagy inducing agent in conjunction with adenovirus treatment of humans. The drug was found to have synergistic effects with oncolytic adenovirus, which coincided with major changes in antitumor T-cell reactivity (ELISPOT) and immunogenic cell death. 22 While of preliminary nature due to limited patient numbers, our data suggest that smaller variation in blood CD8 + /CD4 + proportions post-treatment is associated with more antitumor immunity, as estimated by ELISPOT. One explanation for this could be that in patients where immunosuppression dominates, radical changes in blood lymphocytes can occur, without much consequence to the tumor. Clearly, further studies in more homogeneous patient populations are needed to shed light on these complex and inter-related phenomena. It has been proposed that ELISPOT results could be interpreted in a binary fashion: no change might represent T-cell anergy, while increase and decrease can be understood as T-cell activation, representing either "induction" or "trafficking", depending on which phenomenon dominates with regard to cell numbers in blood. 20, 22, 37 Interestingly, T-cell anergy (as measured by lack of responsiveness in ELISPOT) seems to be associated with larger changes in proportional T-cell subsets in peripheral blood. This could result from a disconnect between the induction of immune responses and productive antitumor activity of T-cells, caused by tumor immunosuppression. 4, 7 In other words, immune response can be induced but this does not necessarily lead to any antitumor activity, if the tumor is very immunosuppressive. This phenomenon has been seen in numerous cancer vaccine trials 2 . Comparison of tumor imaging data and T-cell subpopulations in blood suggested no correlation. This could reflect the problem posed by inflammatory swelling in using tumor size as a surrogate, a phenomenon likely to cause false negatives in assessment of efficacy by imaging. 38 Alternatively or in addition, this finding is compatible with a disconnect between antitumor T-cells and treatment responses, as discussed above, because just looking at the blood omits the effects of the tumor microenvironment. It seems possible that even high numbers of antitumor T-cells would mean little, if the tumor microenvironment is able to inactivate them, or block recruitment to tumors. 4 Moreover, if antitumor T-cells have no relevance because of the ability of the tumor to inactivate them, it would seem logical that they are not regulated as closely as in a situation where they have a meaningful role. By extension, this speculation also applies to antiviral T-cells, as the virus is mostly present in tumors.
We have presented five patient cases with pre-and post-treatment biopsy data available. Analysis of concurrent changes of T cells in peripheral blood and at the tumor proposes a link between these two environments. Interestingly and importantly, the correlations seem to be completely opposite for CD4 + and CD8 + cells. CD4 + cells follow the logic of T-cell trafficking ("down in blood means up in the tumor") whereas CD8 + cells could represent simplistic induction in all compartments ("up everywhere"). These contrasts could be explained to some degree by hypothesizing that CD4 + and CD8 + cells preferentially recognize different targets in the oncolytic viral treatment context. For example, CD4 + cells could receive more activation from tumor epitopes, and unfortunately some of this could be inhibitory signaling through T-Regs. In contrast, CD8 + cells might be more easily induced by virus particles, given the memory response resulting from prior exposure, and the unparalleled ability of viruses to induce adaptive immunity. Alternatively, CD8 + cells might be more prone to general mobilization, while CD4 + cells are not as capable of increasing much in number, as discussed above. We also found increased levels of B-cell marker CD19 in two patients. These findings could be explained by strong costimulation by tumor infiltrating T cells or the specific activity of CD40L transgene. Also, the role of dendritic cells 39, 40 and myeloid derived suppressor cells 41 is important regarding both CD4 + and CD8 + activity. These cell types could in some circumstances have diverging effects on cytotoxic and helper T-cell responses. Studies on tumor-associated macrophages (TAMs) have yielded interesting yet somewhat conflicting results. 11, 42, 43 These results could be at least partly explained by the differing polarization to pro-and antitumor macrophages, or M2 and M1, respectively. The macrophage infiltration and polarization are closely linked to adaptive immunity due to immunosuppression on one hand and antigenpresenting capacities on the other. 44 In our patient series, the largest increases of CD68 + and CD163 + cells at the tumor site were found in the patient who had the best response in terms of imaging and overall survival, and increases in both markers were seen in all three patients with signs of treatment benefits in imaging. These preliminary findings are interesting because they are the first human data suggesting that stimulation of macrophages by human adenovirus could relate to efficacy, but given the complex interactions of macrophages with tumor cells, much work is required to dissect the phenomenon further, especially to understand the mechanisms adenovirus therapy exerts on macrophage recruitment and polarization.
These results offer insight into some of the complicated interdependencies between antiviral and antitumor immunological responses on one hand, and suppressive effects of the tumor on the other. Importantly, our data are from human cancer patients, circumventing many of the uncertainties involving the relevance of murine models with regard to human oncology. We have shown that viral therapy causes substantial alterations in T-cell subsets in peripheral blood, and that generally, there is correlation between CD8 + changes in blood and tumor. In contrast, however, there was inverse correlation in the context of CD4 + cells. Thus, by extension it can be proposed that an increase in the proportion of CD8 + cells in blood has the potential for being a biomarker of relevance, as it correlates with a decrease in the proportion of CD4 + in blood, which correlates with an increase in CD4 + in tumors. Of note, there seemed to be correlation between accumulation of CD4 + cells at the tumor and signs of treatment benefits in our patients, and there was some indication that increased CD4+ staining associated with an increase in monocyte/macrophage lineage markers. Unveiling the activation and cooperation of both the adaptive and the innate immune systems in the context of adenoviral treatments requires further studies. These results demonstrate the importance of thorough analysis of immune cell alterations in the peripheral blood as well as at the tumor site for understanding the mechanism of action of oncolytic virotherapy.
MATERIALS AND METHODS
Patients and samples. Samples from 50 patients treated with oncolytic adenovirus Ad5/3-d24-GMCSF (CGTG-102), Ad5/3-hTERT-CD40L (CGTG-401), or Ad5/3-E2F-d24-GMCSF (CGTG-602) in an Advanced Therapy Access Program 45, 46 were available for analysis. Samples were initially collected as whole blood, followed by extraction of peripheral blood mononuclear cells (PBMC) by gradient centrifugation. Pre-and post-treatment sample collection timeframes were between 28-141 days, average 48.3. Timeframes for different virus treatment groups were following: 28-62 days, average 43.4 (CGTG-102), 28-141 days, average 50.5 (CGTG-401), 35-70 days, average 50.6 (CGTG-602). The differences in collection timeframes between the three virus treatment groups were not significant when tested with ANOVA (P = 0.383). PBMC were then stored in CTL-Cryo medium (Cellular Technology, Shaker Heights, OH) at −140 °C.
Before receiving oncolytic virotherapy, all patients had solid tumors that were progressing after the usual routine therapies, and WHO performance score of less than 3 without any major organ dysfunctions. Exclusion criteria were as previously reported 47 : organ transplant or severe malfunction of vital organ systems, known brain metastasis, human immunodeficiency virus or other major immunosuppression, elevated bilirubin, alanine transaminase or aspartate transaminase increased over x3 upper limit of normal, severe thrombocytopenia, and other severe disease. All patients gave written informed consent.
ATAP -2 × 10 12 VP for CGTG 602. When no contraindications were present, patients were given concomitant low-dose cyclophosphamide to reduce regulatory T-cells. 23 Radiological imaging was performed by contrast-enhanced computed tomography (CT), magnetic resonance imaging, or F18-fluorodeoxyglucose positron emission tomography (F18-FDG-PET-CT) scanning.
Oncolytic adenoviruses. The oncolytic adenoviruses featured here have been previously published. Ad5/3-∆24-GMCSF, Ad5/3-E2F-D24-GMCSF, and Ad5/3-hTERT-E1A-CD40L are serotype 5 adenoviruses capsid-modified with serotype 3 knob. 19, 24, 25 The first two express GM-CSF while Ad5/3-hTERT-E1A-CD40L expresses human CD40 ligand. Viruses were produced according to current good manufacturing practices by Oncos Therapeutics (Helsinki, Finland).
Characterization of T cells from PBMC samples. PBMC samples were washed by transferring frozen samples to 10 ml of phosphate-buffered saline. Samples were then resuspended in 2 ml RPMI 1640 (supplemented with 10% fetal bovine serum, 1% L-glutamine, 1% penicillin-streptomycin) and incubated overnight at 37 °C. After incubation, samples divided to two 1 ml aliquots and one aliquot was stimulated by adding 50 ng/ml phorbol 12-myristate 13-acetate (Sigma-Aldrich, St. Louis, MO) and 1 µg/ ml Ionomycin (Sigma-Aldrich). Samples were supplemented with 1 µl of Brefaldin A (BD Biosciences, San Jose, CA) and incubated for 2 hours.
After stimulation, samples were washed and suspended in stain buffer (phosphate-buffered saline, 2% FBS). Conjugated antibodies against cell surface markers CD3 (Pe-Cy7), CD4 (PerCP-Cy5,5), CD8 (APC-H7), and CD25 (allophycocyanin, all antibodies from BD Biosciences) were added.
Cells were then washed with CellWash buffer (BD Biosciences) and fixed using Cytofix/Cytoperm solution (BD Biosciences). After this, cells were washed and resuspended in Perm/Wash buffer (BD Biosciences). Intracellular markers were stained using conjugated antibodies against FoxP3 (Horizon V450), IL-17A (AF700), IL-10 (PE), and IFN-γ (fluorescein isothiocyanate). After staining, cells were washed with CellWash buffer and suspended in CellfIX buffer (BD Biosciences). Flow cytometry analysis was conducted using LSR Fortessa (BD Biosciences) and data were analyzed with FACSDiva 6.0 Software (BD Biosciences). The gating strategy is outlined in the Supplementary Figure S9. ELISPOT. ELISPOT analysis was performed for the extracted PBMCs as described earlier. 18 PBMCs were stimulated with the human adenovirus serotype 5 penton (HAdV-5; ProImmune, Oxford, UK) to analyze adenovirus-related responses, and with a tumor-associated BIRC5 PONAB peptide Survivin (ProImmune) to detect tumor-specific antigen responses. A total of 10 spot forming units were considered the lower limit of reliable detection for the baseline and difference between pre-and post-treatment samples. ELISPOT result chages between -3 and +3 were interpreted as "no change", less than -3 and more than 3 as decrease and increase in anti-Ad5 or anti-survivin ELISPOT respectively.
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Biopsy samples and immunohistochemical stainings. Pre-and post-treatment core needle biopsies were collected with written informed consent from patients undergoing oncolytic virus treatment. Biopsies were taken in ultrasound or visual guidance depending on the location of the tumor. Tumor sections were immediately fixed in formalin. Immunohistochemical stainings with CD3, CD4, CD8, CD19, CD25, CD68, and CD163 antibodies were performed according to standard protocols using 3,3′-diaminobenzidine (DAB) as detection agent. Collection of biopsies from patients undergoing treatment in ATAP received a positive evaluation by the Helsinki University Central Hospital operational Ethics committee (Dnro 368/13/03/02/2009).
A color information based image processing methodology was applied to quantify the immunohistochemical stainings. The samples were first digitally scanned, annotated for tumorous regions, and then automatically analyzed. Based on the standard color deconvolution, a monochrome channel (CDAB) was extracted, identifying the image pixels stained with DAB and their staining intensities. A threshold value was defined for the CDAB monochrome image to further detect exclusively positively stained cellular regions and to filter out possible unspecific staining. The immunohistochemical samples were quantified by calculating a fraction of positively stained cellular region in the whole region-of-interest, i.e., tumor region. The image-processing pipeline was implemented in matrix laboratory (MATLAB, version R2012b; MathWorks, Natick, MA) numerical computing environment.
Response evaluation. Responses were evaluated from pre-and post-treatment scans performed with CT or positron emission tomography with CT (F18-FDG-PET-CT). RECIST 1.1 criteria with small modifications 20 was used for evaluation of CT results whereas PET criteria were used for the PET-CT results as described earlier. 38 Briefly, responses were graded as progressive disease or progressive metabolic disease (PD/PMD), stable disease or stable metabolic disease (SD/SMD), minor response or minor metabolic response (MR/MMR), and complete response or complete metabolic response (CR/CMR). Patients with CT or PET-CT response evaluation available were further grouped in a binary manner to progressive disease (PD/PMD) and disease control (SD/SMD or better) in order to allow statistical analysis.
Statistical analysis.
Statistical analysis was performed with Microsoft Excel (Microsoft, Redmond, WA) and SPSS v18.0 (SPSS, Chicago, IL). Data from T-cell subpopulations was analyzed with paired t-test. Data from T-cell subpopulation changes using different groups was tested with two tailed t-test. Differences between radiological response groups were analyzed using Mann-Whitney U-test. Overall, survival data were analyzed using log rank test. Relations between blood and tumor biopsy T-cell changes were analyzed using Pearson's correlation coefficient. P values <0.05 were considered statistically significant. Table S1 . The disease control status is associated with less depletion of T-helper cells, smaller increase in cytotoxic T-cells and negative change in regulatory T-cells. Figure S1 . The balance of T lymphocytes in patients receiving oncolytic virotherapy is shifted towards cytotoxic T-cells after the first viral treatment when measured with absolute cell counts. Figure S2 . Changes in T-cell subsets are skewed towards CD4 depletion/CD8 increase after the first viral treatment. Figure S3 . T-helper cells shown as absolute change in flow cytometry events are more often depleted after the first viral treatment. Figure S4 . Differences between pre-and post-treatment levels of Th1-cells and regulatory t-cells display no clear correlation. Figure S5 . Th17 subpopulations in all patients are small and stay unchanged after the viral treatment. Figure S6 . Amount of positive changes in CD4 cells after the viral treatment is unevenly distributed when plotted against pre-and post-treatment sample timeframe. Figure S7 . Amount of negative changes in CD8 cells after the viral treatment is unevenly distributed when plotted against pre-and post-treatment sample timeframe. Figure S8 . Kaplan-Meier survival curves for patient groups with different CD4, CD8, Th1 or Treg change status. Figure S9 . Gating strategy in flow cytometry analysis.
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